Shopping Cart

Remove All

Your shopping cart is currently empty

Ibiglustat

Select Batch

Purity:99.14%

Resource Download

COA HPLC HNMR

Ibiglustat

Catalog No. T4473Cas No. 1401090-53-6

Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Pack Size	Price	Availability
1 mg	$55	In Stock
2 mg	$80	In Stock
5 mg	$163	In Stock
10 mg	$295	In Stock
25 mg	$521	In Stock
50 mg	$755	In Stock
100 mg	$1,060	In Stock
500 mg	$2,120	In Stock
1 mL x 10 mM (in DMSO)	$139	In Stock

Bulk & Custom

Add to Cart

Questions

Related Compound Libraries of "Ibiglustat"

Product Introduction

Bioactivity

Description	Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.
In vitro	Ibiglustat is in phase II Clinical trials for the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy [1].
Alias	Venglustat, SAR402671, GZ402671

Chemical Properties

Molecular Weight	389.49
Formula	C20H24FN3O2S
Cas No.	1401090-53-6

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

DMSO: 50 mg/mL (128.37 mM)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5675 mL	12.8373 mL	25.6746 mL	128.3730 mL
5 mM	0.5135 mL	2.5675 mL	5.1349 mL	25.6746 mL
10 mM	0.2567 mL	1.2837 mL	2.5675 mL	12.8373 mL
20 mM	0.1284 mL	0.6419 mL	1.2837 mL	6.4187 mL
50 mM	0.0513 mL	0.2567 mL	0.5135 mL	2.5675 mL
100 mM	0.0257 mL	0.1284 mL	0.2567 mL	1.2837 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O TargetMol | reagent

mix well and clarify

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc